First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
IPAX-2 is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with external…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Aug 23
IPAX-2 is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with external…
04 Aug 23
Start-up US biotech company tackling rare diseases presents three case studies in France
02 Aug 23
Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates
01 Aug 23
The primary objective of the cOLE study is to assess the efficacy and safety of extended and repeated…
31 Jul 23
The company’s first-in-human investigational new drug applications to hold a single-arm, multicenter, open-label, dose-escalation, and expansion clinical study…
31 Jul 23
Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical trial in China aiming to reach…
25 Jul 23
First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ)…
19 Jul 23
First multi-centre trial, EXCYTE-1, evaluating the potential of Exscientia’s functional precision medicine platform in solid tumour indication
13 Jul 23
The collaboration aims to assess the safety and effectiveness of BBP-398, an investigational SHP2 inhibitor developed by LianBio,…
13 Jul 23
Study aims to create the most robust, multi-omic dataset for patients with NSCLC